Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
38
EKSO Quote, Financials, Valuation and Earnings
Last price:
$4.89
Seasonality move
:
-9.72%
Day range:
$4.71 - $5.00
52-week range:
$2.73 - $14.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.52x
P/B ratio:
1.31x
Volume:
57.7K
Avg. volume:
230.9K
1-year change:
-49.85%
Market cap:
$12.7M
Revenue:
$17.9M
EPS (TTM):
-$3.98
Analysts' Opinion
-
Consensus RatingEkso Bionics Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.75, Ekso Bionics Holdings, Inc. has an estimated upside of 59.47% from its current price of $4.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $4.86.
Fair Value
-
According to the consensus of 2 analysts, Ekso Bionics Holdings, Inc. has 59.47% upside to fair value with a price target of $7.75 per share.
EKSO vs. S&P 500
-
Over the past 5 trading days, Ekso Bionics Holdings, Inc. has overperformed the S&P 500 by 3.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ekso Bionics Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ekso Bionics Holdings, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ekso Bionics Holdings, Inc. reported revenues of $4.2M.
Earnings Growth
-
Ekso Bionics Holdings, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ekso Bionics Holdings, Inc. reported earnings per share of -$0.54.
Enterprise value:
14.9M
EV / Invested capital:
1.02x
Price / LTM sales:
4.52x
EV / EBIT:
--
EV / Revenue:
1.01x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.9M
Return On Assets:
-40.76%
Net Income Margin (TTM):
-70.74%
Return On Equity:
-85.7%
Return On Invested Capital:
-58.51%
Operating Margin:
-33.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $17M | $17.7M | $14.7M | $4.1M | $4.2M | |
| Gross Profit | $8.4M | $9.2M | $7.9M | $2.2M | $2.5M | |
| Operating Income | -$16.1M | -$11.7M | -$11M | -$2.6M | -$1.4M | |
| EBITDA | -$14.8M | -$9.8M | -$9.5M | -$2.2M | -$1M | |
| Diluted EPS | -$1.12 | -$0.65 | -$3.98 | -$0.10 | -$0.54 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.1M | $36.8M | $22.4M | $21.1M | $14.8M | |
| Total Assets | $50.7M | $39.3M | $31.2M | $29.2M | $21.7M | |
| Current Liabilities | $4.7M | $7.9M | $7.8M | $7.5M | $8.9M | |
| Total Liabilities | $11.7M | $10.7M | $15.9M | $14.3M | $12M | |
| Total Equity | $39.1M | $28.6M | $15.3M | $14.9M | $9.7M | |
| Total Debt | $2M | $3.2M | $7.1M | $5.9M | $2.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.1M | -$10M | -$8.9M | -$2.3M | -$2.1M | |
| Cash From Investing | -$5.1M | -$59K | -$83K | -$8K | -$12K | |
| Cash From Financing | -- | $8.4M | $3.4M | $4.7M | -$437K | |
| Free Cash Flow | -$14.3M | -$10.1M | -$9M | -$2.3M | -$2.1M | |
EKSO
Sector
Market Cap
$12.7M
$27.9M
Price % of 52-Week High
32.46%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-32.64%
-1.49%
1-Year Price Total Return
-49.85%
-16.66%
Beta (5-Year)
0.817
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.74
200-day SMA
Buy
Level
$4.76
Bollinger Bands (100)
Buy
Level
3.7 - 5.08
Chaikin Money Flow
Sell
Level
-11M
20-day SMA
Buy
Level
$4.56
Relative Strength Index (RSI14)
Buy
Level
55.94
ADX Line
Buy
Level
11.49
Williams %R
Sell
Level
-14.4654
50-day SMA
Buy
Level
$4.73
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
285.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.688)
Sell
CA Score
(Annual)
Level (-2.1134)
Buy
Beneish M-Score
(Annual)
Level (-30.3142)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.1218)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.
Stock Forecast FAQ
In the current month, EKSO has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EKSO average analyst price target in the past 3 months is $7.75.
-
Where Will Ekso Bionics Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ekso Bionics Holdings, Inc. share price will rise to $7.75 per share over the next 12 months.
-
What Do Analysts Say About Ekso Bionics Holdings, Inc.?
Analysts are divided on their view about Ekso Bionics Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ekso Bionics Holdings, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Ekso Bionics Holdings, Inc.'s Price Target?
The price target for Ekso Bionics Holdings, Inc. over the next 1-year time period is forecast to be $7.75 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EKSO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ekso Bionics Holdings, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EKSO?
You can purchase shares of Ekso Bionics Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ekso Bionics Holdings, Inc. shares.
-
What Is The Ekso Bionics Holdings, Inc. Share Price Today?
Ekso Bionics Holdings, Inc. was last trading at $4.89 per share. This represents the most recent stock quote for Ekso Bionics Holdings, Inc.. Yesterday, Ekso Bionics Holdings, Inc. closed at $4.86 per share.
-
How To Buy Ekso Bionics Holdings, Inc. Stock Online?
In order to purchase Ekso Bionics Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EKSO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EKSO
Sector
P/E ratio
--
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
1.31x
1.81x
Price / LTM sales
4.52x
1.58x
Growth Metrics
EKSO
Sector
Revenue growth
2.37%
4.62%
Earnings growth
-432.55%
10.5%
Revenue (5-year growth)
5.19%
6.5%
Earnings forecast
--
-$0.21
Profitability
EKSO
Sector
Profitability FY 2024
$10.2M
$3.6M
Return on invested capital
-58.51%
-31.87%
Return on assets
-40.76%
-28.18%
Return on equity
-85.7%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Jan
27
Balance Sheet
EKSO
Sector
Total cash
$2.7M
$26.4M
Short term investments
--
$25.7M
Total assets
$26.7M
$76.9M
Long term debt
$2.6M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
